All In Biotech

Drug Trial Radar · NCT04864743

A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

An Open-Label, Multicenter Evaluation of the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in Patients With Severe Hemophilia A.

Last checked: Nov 19, 2026Latest source record: Sep 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Jun 22, 2021

Primary completion

Oct 17, 2021

Study completion Oct 17, 2021

Sponsor

Sponsor type
Industry
First posted
Apr 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the study are to evaluate the Pharmacokinetics,Safety and tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in patients with severe hemophilia A. The secondary objectives are to monitor anti-durg antibodies and anti-PEG antibodies levels in patients with severe hemophilia A

Conditions

  • Severe Hemophilia A

Interventions

  • ADVATEDrug

    a single dose.

  • FRSW117Drug

    a single dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2
  2. Arm1 - T½ from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2
  3. Arm1 - CL from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2
  4. Arm1 - MRT from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2
  5. Arm1 - Incremental recovery from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 216 hours after the end of the infusion forArm1; Pre-dose to 288 hours after the end of the infusion for Arm2
  6. Arm1 - Cmax from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2
  7. Arm1 - T½ from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2
  8. Arm1 - CL from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2
  9. Arm1 - MRT from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2
  10. Arm1 - Incremental recovery from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2
  11. Number of participants with treatment-emergent adverse events (TEAEs).Time frame: assessed up to four weeks after FRSW117 administration.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangzhou, China

  • People's Hospital of Zhengzhou

    Zhengzhou, Henan, China

  • Jinan central hospital

    Jinan, Shandong, China

  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.